Serum miR-423-5p discriminates patients with Parkinson's disease from healthy individuals and is associated with severity and the risk of cognitive dysfunction.
Serum miR-423-5p discriminates patients with Parkinson's disease from healthy individuals and is associated with severity and the risk of cognitive dysfunction.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND AND AIMS: Parkinson's disease (PD) is the most prevalent central nervous system (CNS) movement disorder primarily affecting older populations. It lacks reliable diagnostic biomarkers. Emerging evidence suggests a potential association between miR-423-5p dysregulation and PD development. METHOD: This single-center study enrolled 83 patients with PD and 56 healthy controls. Serum miR-423-5p levels were quantified via real-time quantitative PCR (qPCR) after fasting blood collection. The significance of serum miR-423-5p in disease diagnosis, severity evaluation, and cognitive dysfunction risk prediction was evaluated by ROC curves, logistic regression analysis, and correlation analyses. RESULTS: A significant downregulation of miR-423-5p was observed in patients with PD compared to healthy controls, which effectively discriminated patients with PD (sensitivity of 84.34% and specificity of 76.79%) from healthy individuals. Patients with PD who had cognitive dysfunction showed lower serum miR-423-5p levels. Patients with higher MDS-UPDRS-III, HAMA, HAMD, and SCOPA-AUT scores showed lower miR-423-5p expression. Participants with higher MoCA scores showed higher serum miR-423-5p levels. Both miR-423-5p and the Hoehn-Yahr (HY) stage were identified as risk factors for cognitive dysfunction in patients with PD. CONCLUSIONS: Serum miR-423-5p levels showed potential as a clinical biomarker for assisting the early detection and progression monitoring of PD.